tetano
Editor, Senior Moderator
Sci Rep
. 2022 Feb 18;12(1):2784.
doi: 10.1038/s41598-022-06752-0.
Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module
Hye Kyung Lee[SUP] #[/SUP][SUP] 1 [/SUP], Ludwig Knabl[SUP] #[/SUP][SUP] 2 [/SUP], Ludwig Knabl Sr[SUP] 3 [/SUP], Manuel Wieser[SUP] 4 [/SUP], Anna Mur[SUP] 5 [/SUP], August Zabernigg[SUP] 5 [/SUP], Jana Schumacher[SUP] 6 [/SUP], Sebastian Kapferer[SUP] 5 [/SUP], Norbert Kaiser[SUP] 6 [/SUP], Priscilla A Furth[SUP] 7 [/SUP], Lothar Hennighausen[SUP] 8 [/SUP]
Affiliations
Abstract
Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. While viral infections elicit a conserved immune response, it is not known whether SARS-CoV-2 variants, which display enhanced binding to the ACE2 receptor and reduced neutralizing activity by vaccine-elicited antibodies, prompt specific genomic immune responses. To test this, we generated and investigated the transcriptomes in BCs from hospitalized patients infected with either the Alpha variant (n = 36) or with the Alpha variant that had acquired the E484K escape mutation (Alpha+E484K) (n = 13). We identified a gene module preferentially activated in patients infected with the Alpha+E484K variant and in patients infected with the Beta (n = 9) and Gamma (n = 3) variants that also carry by the E484K escape mutation. The E484K signature was enriched for genes preferentially expressed in monocytes and linked to severe viral infection. However, both cohorts had undergone similar treatments and no differences in disease severity were reported suggesting that this signature reflects a variant response and does not necessarily associate with disease outcome. Additionally, longitudinal transcriptome analyses revealed a more persistent retention of immune signatures in Alpha+E484K patients throughout the entire course of COVID-19 disease and convalescence. While the OAS1 Neanderthal mutation has been linked to a milder COVID-19 pathology, we did not identify significant immune transcriptomes differences in the 25 patients homozygous for this mutation. Our study offers insights into distinct molecular immune responses elicited by SARS-CoV-2 variants carrying the E484K escape mutation throughout the COVID-19 disease.
. 2022 Feb 18;12(1):2784.
doi: 10.1038/s41598-022-06752-0.
Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module
Hye Kyung Lee[SUP] #[/SUP][SUP] 1 [/SUP], Ludwig Knabl[SUP] #[/SUP][SUP] 2 [/SUP], Ludwig Knabl Sr[SUP] 3 [/SUP], Manuel Wieser[SUP] 4 [/SUP], Anna Mur[SUP] 5 [/SUP], August Zabernigg[SUP] 5 [/SUP], Jana Schumacher[SUP] 6 [/SUP], Sebastian Kapferer[SUP] 5 [/SUP], Norbert Kaiser[SUP] 6 [/SUP], Priscilla A Furth[SUP] 7 [/SUP], Lothar Hennighausen[SUP] 8 [/SUP]
Affiliations
- PMID: 35181735
- DOI: 10.1038/s41598-022-06752-0
Abstract
Fast-spreading variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) energize the COVID-19 pandemic. While viral infections elicit a conserved immune response, it is not known whether SARS-CoV-2 variants, which display enhanced binding to the ACE2 receptor and reduced neutralizing activity by vaccine-elicited antibodies, prompt specific genomic immune responses. To test this, we generated and investigated the transcriptomes in BCs from hospitalized patients infected with either the Alpha variant (n = 36) or with the Alpha variant that had acquired the E484K escape mutation (Alpha+E484K) (n = 13). We identified a gene module preferentially activated in patients infected with the Alpha+E484K variant and in patients infected with the Beta (n = 9) and Gamma (n = 3) variants that also carry by the E484K escape mutation. The E484K signature was enriched for genes preferentially expressed in monocytes and linked to severe viral infection. However, both cohorts had undergone similar treatments and no differences in disease severity were reported suggesting that this signature reflects a variant response and does not necessarily associate with disease outcome. Additionally, longitudinal transcriptome analyses revealed a more persistent retention of immune signatures in Alpha+E484K patients throughout the entire course of COVID-19 disease and convalescence. While the OAS1 Neanderthal mutation has been linked to a milder COVID-19 pathology, we did not identify significant immune transcriptomes differences in the 25 patients homozygous for this mutation. Our study offers insights into distinct molecular immune responses elicited by SARS-CoV-2 variants carrying the E484K escape mutation throughout the COVID-19 disease.